Table 2. Incidence and relative risk of FAEs with EGFR-MoAbs according to tumor types, EGFR-MoAbs and phases of trials.

Groups	Studies, n	Fatal Adverse Events, No./Total No.		Incidence (95%CI), %	OR (95% CI)	Statistical model	P value
		EGFR-MoAbs	Control
Overall	21	119/7841	87/7775	1.7 ( 1.1-2.5)	1.37 (1.04-1.81)	Fixed	0.024
Tumor types
CRC	11	87/5886	64/5879	1.6 (0.9-2.7)	1.37 (0.99-1.89)	Fixed	0.058
NSCLC	5	19/1021	15/1027	2.5 (1.1-5.6)	1.28(0.65-2.53)	Fixed	0.457
Head and neck cancer	2	10/427	7/427	1.4 (0.1-20.5)	1.42 (0.54-3.73)	Fixed	0.482
EGFR-MoAbs
Cetuximab	17	104/6016	78/5937	2.0 (1.3-3.2)	1.34 (1.00-1.80)	Fixed	0.052
Panitumumab	4	15/1825	9/1838	0.9 (0.5-1.7)	1.66 (0.75-3.71)	Fixed	0.214
Phases of trials
Phase II	5	4/294	4/232	2.8 (1.1-6.7)	0.95 (0.23-3.87)	Fixed	0.939
Phase III	16	115/7547	83/7543	1.6 (1.0-2.5)	1.40 (1.05-1.85)	Fixed	0.021

Abbreviations: NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; OR, odds ratio.